Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: Results from a prospective, randomized, open-label, crossover study (PrefMab)

Annals of Oncology

Volumn 28, Issue 4, 2017, Pages 836-842

  Rummel, M ^a   Kim, T M ^b   Aversa, F ^c   Brugger, W ^d,j   Capochiani, E ^e   Plenteda, C ^c   Re, F ^f   Trask, P ^g   Osborne, S ^h   Smith, R ^h   Grigg, A ⁱ  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b Seoul National University Hospital   (South Korea)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Center for Hematology   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g GENENTECH INC   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ AUSTIN HOSPITAL   (Australia)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

Chemotherapy; DLBCL; FL; Rituximab; Subcutaneous

Indexed keywords

BENDAMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY SATISFACTION QUESTIONNAIRE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIFFUSE LARGE B CELL LYMPHOMA; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PATIENT PREFERENCE; PATIENT PREFERENCE QUESTIONNAIRE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE; SCORING SYSTEM; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PATIENT PREFERENCE; PROSPECTIVE STUDIES; RITUXIMAB;

EID: 85019136418     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw685     Document Type: Article

References (20)

1. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
2. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
3. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.
4. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
5. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
6. Mabthera SmPC, https://www.medicines.org.uk/emc/ (1 August 2016, date last accessed).
7. Rituxan PI, http://www.fda.gov/ (1 August 2016, date last accessed).
8. De Cock E, Kritikou P, Sandoval M et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE 2016; 11: e0157957.
9. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as firstline treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
10. Pivot X, Gligorov J, Muller V et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962-970.
11. Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 2013; 109: 1556-1561.
12. Davies A, Merli F, Mihaljevic B et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014; 15: 343-352.
13. Salar A, Avivi I, Bittner B et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol 2014; 32: 1782-1791.
14. Roche; http://www.roche.com/media/store/releases/med-cor-2014-03-28.html (1 August 2016, date last accessed).
15. Lugtenburg P, Rueda A, Avivi I et al. Subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated diffuse large B-cell lymphoma: efficacy and safety results from the phase IIIB MABEASE study. Haematologica 2015; 100: S483.
16. Trask PC, Tellefsen C, Espindle D et al. Psychometric validation of the cancer therapy satisfaction questionnaire. Value Health 2008; 11: 669-679.
17. Theodore-Oklota C, Humphrey L, Wiesner C et al. Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. PPA 2016; 10: 1767-1776.
18. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
19. Pivot X, Gligorov J, Muller V et al. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014; 25: 1979-1987.
20. Lugtenburg P, Rueda A, Avivi I et al. Patient preference with subcutaneous vs intravenous rituximab combined with CHOP for untreated diffuse large B-cell lymphoma: results from the phase IIIb MABEASE study. Hematol Oncol 2015; 33: A383.